North America Glioma Market Overview

The North America glioma market was valued at USD 1.03 Billion in 2025 and is projected to reach USD 1.41 Billion by 2035 , expanding at a CAGR of 3.22% during the forecast period of 2026–2035 . North America commands a dominant share of the global glioma market, driven by advanced healthcare infrastructure, high glioma incidence rates, and accelerated regulatory approvals of next-generation therapies.

Glioma is the most prevalent type of primary brain tumor in adults, accounting for nearly 80% of all malignant brain tumors in North America . The rising burden of glioblastoma (GBM), astrocytoma, and oligodendroglioma —alongside growing investment in precision oncology and immunotherapy—continues to reshape the North America glioma treatment landscape.

Landmark approvals by the FDA for IDH-mutant glioma therapies, combined with ongoing clinical trials by key players such as Pfizer, Roche, AstraZeneca, and Bristol-Myers Squibb, are expected to sustain market momentum through 2035. The United States leads regional demand, supported by robust reimbursement structures and expanding neuro-oncology research pipelines.

Key Market Statistics

• North America Market Size (2025): $1.03B
• CAGR (2026–2035): 3.22%
• Projected Market Size (2035): $1.41B
• Share of Malignant Brain Tumors: ~80%

Key Market Drivers: What Is Fueling North America Glioma Market Growth?

Several structural and clinical forces are propelling the North America glioma market during the 2026–2035 forecast period.

Rising Innovation in Glioma Therapies

Development of IDH inhibitors, VEGF-targeted agents, and CAR-T cell immunotherapies is expanding treatment options for low-grade and high-grade gliomas, creating new revenue streams for pharmaceutical companies.

Increased Regulatory Approvals of Advanced Medications

FDA accelerated approvals for glioblastoma and IDH-mutant astrocytoma treatments, including vorasidenib and bevacizumab-based regimens, are directly boosting North America glioma drug market revenues.

Growing Incidence of Brain Tumors in North America

An estimated 25,000+ new primary malignant brain tumor diagnoses are reported annually in the United States alone, with glioblastoma representing the largest sub-segment, driving sustained demand for diagnostic and therapeutic solutions.

Advances in Neuroimaging and Early Diagnosis

Widespread adoption of high-resolution MRI, functional imaging, and AI-assisted CT analysis enables earlier glioma detection, improving treatment outcomes and increasing per-patient therapy spending.

Strong Pipeline of Clinical Trials and R&D Investment

Major pharmaceutical players are investing heavily in Phase II and Phase III glioma trials focused on combination therapies, tumor treating fields (TTF), and checkpoint inhibitors, sustaining long-term market expansion.

Explore the Report – Free Sample with Detailed TOC Available

North America Glioma Market Segmentation

The North America Glioma Market Report and Forecast 2026–2035 provides detailed segmentation analysis across multiple dimensions.

By Type

• Astrocytoma
• Oligodendroglioma
• Glioblastoma

By Diagnosis

• Angiograms
• MRI
• CT Scan
• Surgical Biopsy
• Others

By Treatment Type

• Chemotherapy
• Radiation Therapy
• Surgery

By Route of Administration

• Oral
• Parenteral

By Country

• United States
• Canada

Glioblastoma Segment: The Dominant Revenue Driver

Glioblastoma multiforme (GBM) holds the largest share of the North America glioma market by type . As a Grade IV astrocytoma , GBM has the highest incidence rate among gliomas and demands the most aggressive and costly treatment protocols, including temozolomide chemotherapy, radiation therapy, and emerging immunotherapies .

The glioblastoma treatment market in North America is expected to remain the primary revenue contributor through 2035 , supported by FDA-approved therapies and active pipeline candidates from Roche, Merck, and Bristol-Myers Squibb .

MRI: The Gold Standard in Glioma Diagnosis

Magnetic Resonance Imaging (MRI) dominates the diagnosis segment of the North America glioma market. Multiparametric MRI techniques—including diffusion-weighted imaging (DWI), perfusion MRI, and MR spectroscopy—allow precise tumor grading, surgical planning, and post-treatment monitoring.

The growing installation base of 3T and 7T MRI systems across U.S. academic medical centers and neuro-oncology centers is expected to sustain MRI’s segment leadership throughout the forecast period.

Chemotherapy: Leading North America Glioma Treatment Market

Chemotherapy remains the backbone of the North America glioma treatment market, with temozolomide (TMZ) serving as the standard-of-care for newly diagnosed GBM since its FDA approval.

Oral alkylating agents and novel IDH-mutant-targeted drugs such as vorasidenib are driving segment growth. Meanwhile, the parenteral route of administration is gaining traction for bevacizumab (Avastin) and other biologics administered in hospital and infusion-center settings.

Country-Level Analysis: United States and Canada

United States Glioma Market

The United States glioma market represents the largest country-level segment within North America, accounting for the majority of regional revenues. The U.S. benefits from world-class neuro-oncology centers, including:

• MD Anderson Cancer Center
• Mayo Clinic
• Memorial Sloan Kettering

Key drivers include:

• High per-capita healthcare expenditure
• Favorable reimbursement policies under Medicare/Medicaid
• Widespread adoption of advanced neuroimaging
• Extensive clinical trial networks

The United States also leads globally in glioma biomarker research, including:

• IDH1/IDH2 mutation testing
• MGMT methylation analysis
• 1p/19q codeletion profiling

Canada Glioma Market

The Canada glioma market is the second-largest country segment, supported by the country’s publicly funded healthcare system and increasing investment in precision oncology infrastructure.

Collaborations with institutions such as:

• Princess Margaret Cancer Centre
• Montreal Neurological Institute

are accelerating glioma research and clinical adoption of emerging therapies.

Canada’s universal healthcare coverage ensures access to standard treatments such as temozolomide, radiation therapy, and surgical resection, though access to cutting-edge targeted therapies and clinical trials remains somewhat more limited than in the United States.

North America Glioma Market: Key Companies and Competitive Landscape

The North America glioma market competitive landscape includes several global pharmaceutical and biotechnology leaders actively investing in approved therapies and pipeline drugs.

Key Companies

• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• Merck & Co., Inc.
• Roche Holding AG
• Bristol-Myers Squibb
• Amgen Inc.
• AstraZeneca PLC
• Eli Lilly and Company
• AbbVie Inc.
• Key Surgical Inc.

Competitive Strategy Highlights

Roche Holding AG
Bevacizumab (Avastin) for recurrent GBM and anti-PD-L1 combination studies.

Bristol-Myers Squibb
Nivolumab (Opdivo) checkpoint inhibitor trials in glioblastoma.

Merck & Co.
Pembrolizumab (Keytruda) combination regimens in glioblastoma.

AstraZeneca
PARP inhibitor and DNA damage repair pathways targeting IDH-mutant glioma.

Novartis AG
CDK4/6 inhibitors and targeted therapy research for glioma subtypes.

AbbVie Inc.
EGFRvIII-targeted antibody-drug conjugate research in glioblastoma.

North America Glioma Market Challenges and Restraints

Despite robust growth projections, the North America glioma market faces several challenges.

Blood-Brain Barrier Drug Delivery Challenge

The blood-brain barrier (BBB) restricts penetration of many chemotherapy agents into CNS tumors. Even with advances such as nanoparticle delivery and convection-enhanced delivery (CED), effective CNS drug delivery remains a major challenge.

High Treatment Costs and Reimbursement Gaps

Novel therapies such as checkpoint inhibitors, CAR-T treatments, and IDH inhibitors carry high treatment costs. Coverage gaps under private insurance and Medicare/Medicaid may limit access for certain patient populations.

Poor Prognosis Limits Therapy Duration

Glioblastoma has a median survival of 14–16 months, even with standard treatment. This short treatment window limits revenue-per-patient potential, moderating overall market growth.

FAQ

Q.1 What is the North America glioma market size in 2025?
USD 1.03 Billion in 2025.

Q. 2 What is the projected North America glioma market value by 2035?
USD 1.41 Billion by 2035.

Q.3 What CAGR is the North America glioma market expected to grow at?
3.22% CAGR during the forecast period of 2026–2035.

Q.4 What is the most common malignant brain tumor type in North America?
Glioma accounts for nearly 80% of malignant brain tumors in North America.

Q.5 Which glioma type holds the largest market share in North America?
Glioblastoma (GBM) is the dominant segment in the North America glioma market.

Q.6 What diagnostic method is most widely used for glioma detection?
Magnetic Resonance Imaging (MRI) is the gold standard for glioma diagnosis.

Q.7 Which treatment type leads the North America glioma treatment market?
Chemotherapy, particularly temozolomide-based therapy, leads the treatment segment.

Q.8 Which country dominates the North America glioma market?
The United States holds the largest share of the North America glioma market.

About Us

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analysis provides the essential framework for organizations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organization remains agile, proactive, and poised for success in today's competitive market.

Don't miss the opportunity to elevate your business intelligence and strengthen your strategic planning. Secure your organization's future success by acquiring one of our Expert Market Research reports today.

Media Contact

Company Name: Claight Corporation
Contact Person: Lalit Sen, Business Consultant
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com